20 articles
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
Scientists discover how blocking CD40-CD40L pathway reduces dangerous clotting in antiphospholipid syndrome patients.
A completed Phase 3 trial tests placental MSC secretome injections against placebo in 60 GvHD patients at an Iranian hospital.
New research identifies Lp-PLA2 enzyme as therapeutic target for deadly lung disease affecting millions of workers worldwide.
Natural flavonoid fisetin activates mitophagy and xenophagy pathways to restrict intracellular Salmonella growth in immune cells.
Structural biology uncovers the exact amino acid motif causing species-specific drug failures, enabling transgenic mouse models for better P2X7 drug testing.
New research reveals how SIRT2 regulates T cell responses, potentially improving cancer immunotherapy and immune function.
Scientists identify key mechanism that determines why some immune thrombocytopenia patients maintain remission after stopping treatment.
Pyruvate, a core metabolic molecule, suppresses interferon signaling by directly modifying STAT1 — linking metabolism to immune control.
A mechanistic deep-dive into cutting-edge anti-inflammaging interventions — from senolytic pharmacology and precision cytokine targeting to partial reprogramming strategies that aim to restore youthful immune homeostasis.
A phase 1/2 trial finds low-dose oral NMN safely raises platelet counts in steroid-refractory ITP via a novel immunometabolic mechanism.
Expert commentary on pemphigus foliaceus, a rare autoimmune blistering disease affecting skin health and immune function.
Researchers uncover how the STING immune pathway triggers mitochondrial fragmentation and DNA release, fueling deadly lung inflammation in sepsis.
A Phase 1 pilot trial explores whether the IL-12/23 blocker ustekinumab is safe and can reduce systemic inflammation in Sjögren's patients.
Scientists discover serotonin's role in making cancer treatments less effective, opening new therapeutic possibilities.
Senescent T cells fuel psoriasis, eczema, and rosacea through toxic secretions. New therapies may finally break the cycle.
Icotrokinra, a breakthrough oral peptide targeting IL-23, demonstrates significant skin clearance in psoriasis with sustained benefits through 52 weeks.
Oral peptide targeting IL-23 receptor shows superior efficacy vs placebo and deucravacitinib in moderate-to-severe plaque psoriasis.
Go beyond inflammaging basics to understand how aging reshapes immune cell populations, triggers the SASP, and locks the body into a state of chronic low-grade inflammation at the molecular level.
New research reveals how immune cells use cysteine for both antioxidant defense and energy production, with major implications for cancer treatment.
